Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 31.28% | 35.71% | 31.82% | 29.43% | 20.22% |
| Total Depreciation and Amortization | 29.81% | 55.86% | 90.75% | 96.32% | 49.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.57% | -39.01% | -32.91% | -34.85% | 14.45% |
| Change in Net Operating Assets | -88.62% | 146.80% | 327.99% | 459.73% | 946.69% |
| Cash from Operations | -52.34% | 85.87% | 79.92% | 75.53% | 74.23% |
| Capital Expenditure | 92.04% | 93.39% | 83.42% | 28.15% | -96.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -122.49% | -155.53% | -143.07% | -30.11% | 26.32% |
| Cash from Investing | -133.36% | -177.07% | -154.08% | -30.72% | 12.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46,190.74% | 39,368.95% | 30,996.27% | -1.36% | 105.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.90% | -26.89% | -27.19% | 3.64% | -25.16% |
| Cash from Financing | 268.46% | 263.57% | 268.25% | 3.65% | -24.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -235.16% | -542.24% | -206.99% | 88.49% | 114.19% |